United Kingdom-based Oncimmune Holdings has signed an exclusive commercial collaboration with Russia-based R-Pharm JSC.

It was reported on Friday that the contract has been signed to use Oncimmune's EarlyCDT Lung for the early detection of lung cancer in Russia and the member states of the Eurasian Customs Union (Republic of Belarus, Kazakhstan, Armenia and Kyrgyzstan).

According to the terms of the contract, Oncimmune has granted an option to R-Pharm to extend the use of EarlyCDT Lung into the Commonwealth of Independent States countries of Azerbaijan, Turkmenistan, Tajikistan, Ukraine, Uzbekistan, and Georgia. The five-year initial term intends to generate revenues of around GBP5m, including milestone payments of GBP2.75m during this period. R-Pharm will commercialise EarlyCDT Lung in both lung cancer screening and nodule risk assessment in the region.